Xaira Therapeutics

Xaira Therapeutics: AI-Native Drug Discovery Foundation Lab

Xaira Therapeutics is AI drug discovery company applying foundation models to protein and molecular design. AI drug discovery has been promised for a decade — Recursion, Insitro, Atomwise — without breakout therapeutic success. Xaira's bet is that frontier-scale generative models for proteins, combined with integrated wet-lab capacity and a CEO with deep clinical-development experience, will finally translate computational gains into approved therapies. The $1B seed is investor conviction that this team can do what earlier waves could not.

Key Features

• AI drug discovery company applying foundation models to protein and molecular design
• Founded in 2024, headquartered in the San Francisco Bay Area
• Led by CEO Marc Tessier-Lavigne (former Stanford President, former Chief Scientific Officer at Genentech)
• Raised approximately $1 billion in seed funding in April 2024 — the largest seed round in biotech AI history
• Investors include Foresite Capital, ARCH Venture Partners, NEA, Lux Capital, Sequoia Capital, and SV Angel
• Generative protein design models — extends Baker Lab (UW) RoseTTAFold heritage to therapeutic targets
• Integrated drug-discovery platform combining wet-lab automation with computational protein/molecule design

Ideal Use Case

Pharmaceutical R&D leaders, biotech investors, and computational biologists tracking the next generation of AI-native drug discovery — Xaira's combination of generative protein design, integrated wet labs, and Tessier-Lavigne's leadership makes it one of the most-watched AI biotech bets of the decade.

Why Use Xaira Therapeutics

AI drug discovery has been promised for a decade — Recursion, Insitro, Atomwise — without breakout therapeutic success. Xaira's bet is that frontier-scale generative models for proteins, combined with integrated wet-lab capacity and a CEO with deep clinical-development experience, will finally translate computational gains into approved therapies. The $1B seed is investor conviction that this team can do what earlier waves could not.

FAQ

Q: Who leads Xaira Therapeutics? A: Marc Tessier-Lavigne — former Stanford University President and former Chief Scientific Officer at Genentech — is CEO.

Q: How much has Xaira raised? A: Approximately $1 billion in seed funding announced in April 2024, the largest seed round in biotech-AI history.

Q: Who are Xaira's investors? A: Foresite Capital and ARCH Venture Partners co-led; NEA, Lux Capital, Sequoia Capital, and SV Angel participated.

Q: What does Xaira do? A: Xaira applies foundation-scale generative AI models to protein and small-molecule design, combined with integrated wet-lab automation, to accelerate therapeutic discovery.

Q: Is Xaira working on specific diseases? A: Xaira has not publicly disclosed a target therapeutic area pipeline as of mid-2026; the platform is being built before specific programs are announced.

tl;dr

Xaira Therapeutics is the $1B-seeded AI drug discovery foundation lab founded in 2024 by Marc Tessier-Lavigne (ex-Stanford President, ex-Genentech). Backed by Foresite + ARCH + NEA + Lux + Sequoia. Combines generative protein design with integrated wet-lab infrastructure for therapeutic discovery.

Related

Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Xaira Therapeutics is also tracked on Crunchbase.